5 results about "Apolipoprotein B" patented technology

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

The application discloses a kind of lipoprotein detection reagent and lipoprotein detection method, it is related to biochemical detection technical field, the lipoprotein detection reagent includes R1 reagent and R2 reagent, wherein, the R1 reagent includes anti apolipoprotein B antibody, the R2 reagent includes latex microsphere coated with lipoprotein specificity antibody. Wherein, anti apolipoprotein B antibody can preliminarily enrich target lipoprotein and form immune complex to amplify detection signal, and lipoprotein specificity antibody can specifically recognize target protein and form immune complex-lipoprotein specificity antibody-latex microsphere complex, further amplify detection signal, significantly improve the detection sensitivity of reagent.

The invention discloses an apolipoprotein B (ApoB) antibody related to oxidized low density lipoprotein (Ox-LDL) or a functional fragment of the apolipoprotein B antibody, and an application of the apolipoprotein B antibody and the functional fragment. The anti-Ox-ApoB antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to Ox-ApoB, and can be used for detecting Ox-ApoB and / or Ox-LDL and used for auxiliary diagnosis of atherosclerosis by taking Ox-ApoB and / or Ox-LDL as a marker.

A bispecific nucleic acid molecule comprising at least two double stranded inhibitory ribonucleic acid (RNA) molecules that silence by RNA interference apolipoprotein B (ApoB) and diacylglycerol O acyltransferase 2 (DGAT2) wherein said at least two double stranded inhibitory RNA molecules are linked by a DNA linker molecule that has a melting temperature (TM) of approximately 73oC. The use of such dual siRNA constructs in treating cardiovascular related conditions including hypercholesterolemia is further claimed. [Fig. 2A]

This invention belongs to the fields of organic chemistry, medicinal chemistry, and pharmacology, specifically relating to the synthesis of lometapeptide bioelectron isosteres and their application in the preparation of therapeutic drugs for lipid-lowering diseases. A method for preparing lometapeptide bioelectron isosteres mainly includes six steps: 1) Using A and B as starting materials, under nickel catalysis and the action of phosphine ligands, a reaction occurs... endo The reaction [2+2] yielded intermediate I; 2) Intermediate I underwent intramolecular cyclization under thioxanthracene-9-one and photocatalysis to yield intermediate II; 3) Intermediate II was oxidized under alkaline potassium permanganate to yield intermediate III; 4) Intermediate III and C reacted under the action of a condensing agent to prepare amide intermediate IV; 5) Intermediate IV was debenzylated under the action of palladium on carbon and a hydrogen source to prepare amine intermediate V; 6) Intermediate V and D under alkaline conditions underwent a substitution reaction to obtain the final product, lometapetine bioelectron isostere VI. This bioelectron isostere can dose-dependently inhibit the secretion of apolipoprotein B in HepG2 cells and exhibits good kinetic solubility. This compound shows promise for development as a therapeutic drug for hypercholesterolemia-related diseases.